The CHBT Report:
China Economic Review’s Company Reports can and have moved the markets through our on-the-ground authoritative and INDEPENDENT research.  This report, dated on Mar 2011, analyses China Biotics (CHBT.NASDAQ). This issue focuses on China Biotics’ position in the domestic probiotics market. In particular, we carried out due diligence work distribution network, production capacity, customer base, revenue breakdown etc. We conduct analysis and take a perspective on the following key issues:

• China Biotics’ distribution channels for its retail products.
• China Biotics’ Shanghai production facility.
• Other issues regarding China Biotic…
• Our conclusion on the stock: whether to buy, hold or sell.

Anyone who has an interest in USA listed China stocks needs to buy this report now and see the value our research gives you (and your bottom line).

Company Description:
China-Biotics, Inc. engages in the research, development, production, marketing, and distribution of probiotics products in the People\'s Republic of China. Its products contain live microbial food supplements, which beneficially affect the host by improving its intestinal microbial balance. The company serves individual customers; and institutional customers, such as dairy manufacturers, animal feed manufacturers, pharmaceutical companies, and food companies. It distributes its retail products directly, as well as through distributors in the greater Shanghai area under the Shining brand. As of March 31, 2010, the company had 111 Shining branded outlets in Shanghai and 12 other cities in China. China-Biotics, Inc. was founded in 1999 and is based in Pudong, the Peoples Republic of China. (Source: Yahoo Finance!)

Sector: Healthcare
Industry: Drug Manufacturers - Other